7:00 am 

REGISTRATION & NETWORKING BREAKFAST

​

7:30 am 

LONGWOOD FUND INTRODUCTION

Aleks Radovic-Moreno, Partner, Longwood Fund

​​

8:00 am 

PHARMA PIPELINE SOURCING

Fawzi Benzaghou, SVP, Global Head, Oncology, Ipsen

Kathy Fernando, SVP, Global Head, Pfizer Ignite 

Pallavi Garg, Head, US Oncology Business Unit, Takeda

John Pottage, Lead Scientific Consultant, INTREPID Alliance
​Moderator: Michelle Longmire, CEO, Medable​

​

8:30 am 

TARGETING GLP-1

David Moller, Former Head, Metabolic Disease R&D, Eli Lilly

Jørgen Petersen, Senior Partner, Novo Holdings

Raymond Stevens, CEO, Structure Therapeutics

Moderator: Kyle Lefkoff, General Partner, Boulder Ventures

​

8:50 am 

LEVERAGING TECHNOLOGY TO ADVANCE THE PIPELINE

Jason Cole, CEO, SalioGen Therapeutics

Hanadie Yousef, CEO, Juvena Therapeutics

Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute

Ashley Zehnder, CEO, Fauna Bio 

Moderator: Chandra Ramanathan, Head, External Innovation, Danaher 

​​

9:20 am 

ACCELERATING DRUG DISCOVERY

Daniel Dornbusch, CEO, Excision BioTherapeutics 

Frank Haluska, CEO, Kestrel Therapeutics 

Jennifer Michaelson, CSO, Cullinan Therapeutics

Brian Safina, CEO, Magnet Biomedicine

Moderator: Harvey Berger, CEO, Kojin Therapeutics

​

9:50 am 

NETWORKING BREAK 

​

10:20 am 

TARGETED MERGERS & ACQUSITIONS 

Jeff Capello, former CFO, Biogen

Jessica Chutter, Managing Director, Vice Chair, Biotechnology Investment Banking, Morgan Stanley

Raj Khunkhun, Head, Neuroscience BD, Takeda 

Chris Sheldon, SVP, Global Head, BD, GSK

Moderator: Philippe Lopes-Fernandes, CBO, Ipsen

​​

10:50 am 

ALIGNING WITH REGULATORY AUTHORITIES

Jessica Ballinger, CEO, Lyndra Therapeutics

Ned Braunstein, EVP, Regulatory Affairs & Global Patient Safety, Regeneron

Peter Hutt, General Counsel (former), FDA

Thomas Lonngren, former Executive Director, EMA

Moderator: DA Gros, CEO, Eledon Therapeutics

​

11:20 am 

PATIENT-CENTRIC DEVELOPMENT

Craig Bunnell, CMO, Dana-Farber Cancer Institute

Caroline Kant, CEO, EspeRare Foundation

Sarah Sheikh, Head, Global Development & SVP, Neuroscience, Takeda 

Brandon Turunen, CTO, Solu Therapeutics

Moderator: Ariel Katz, CEO, H1

​​

11:50 am 

FIRESIDE CHAT

Levi Garraway, CMO, Roche Genentech

Robert Plenge, EVP, Chief Research Officer, Head of Research, Bristol Myers Squibb

George Yancopoulos, President & CSO, Regeneron

Bob Weinberg, Founding Member, Whitehead Institute, MIT

Moderator: Christoph Westphal, General Partner, Longwood Fund​

​

12:20 pm 

NETWORKING LUNCHEON

​

1:00 pm 

DRIVING PRODUCTIVITY IN R&D

Gina Consylman, R&D, CFO & COO, Takeda

Ashley Lakner, Head, Oncology, pRED, Roche

Nello Mainolfi, CEO, Kymera

Joanna Stanicka, CEO, Axonis

Moderator: Yiannis Kiachopoulos, CEO, Causaly

​

1:30 pm 

FIRESIDE CHAT

Alan Garber, President, Harvard University

Sally Kornbluth, President, MIT

Jim Reddoch, CSO, Royalty Pharma

Moderator: Christoph Westphal, General Partner, Longwood Fund 

​

1:50 pm 

IDENTIFYING NEXT GENERATION THERAPEUTICS

​Rosana Kapeller, CEO, Rome Therapeutics

Mark Rus, CEO, Delix Therapeutics

Oliver Rosen, CMO, Akamis Bio

Paul Peter Tak, CEO, Candel Therapeutics 

Moderator: Brian Taylor, CEO, SmartLabs

​

2:20 pm 

DEVELOPING AN EFFECTIVE BOARD

David Donabedian, Executive Partner, Interim NewCo CEO, Longwood Fund

Nenad Grmusa, CEO, Dem BioPharma

Tamar Thompson, Head, Global Corporate Affairs, Alexion 

Leslie Williams, CEO, hC Bioscience

​Moderator: Luba Greenwood, Managing Director, Binney Street Capital, Dana-Farber Cancer Institute

​

2:50 pm 

NETWORKING BREAK

​​

3:15 pm

NON-PROFIT SPOTLIGHT

Brad Margus, Founder & Volunteer Board Chair, A-T Children’s Project

​

3:20 pm

FIRESIDE CHAT: PHARMA R&D

Fiona Marshall, President, Biomedical Research, Novartis

Marcus Schindler, CSO & EVP, Research & Early Development, Novo Nordisk 

Co-Moderator: Kailash Swarna, Managing Director, Accenture

Christoph Westphal, General Partner, Longwood Fund 

                                                                                                 

3:40 pm

BIOMANUFACTURING: PLANNING FOR FUTURE SUCCESS 

Al Gianchetti, CEO, XyloCor

Marinna Madrid, Chief Product Officer, CellinoBio

Avi Nandi, President, Cell & Gene Therapy, SK pharmtechco

Hari Pujar, COO, Tessera Therapeutics

Moderator: Andrew Obenshain, CEO, bluebird bio​​

​

4:10 pm

THE EVOLVING DEAL-MAKING LANDSCAPE

Jie D’Elia, CEO, SystImmune 

Amanda Kay, Senior Partner & Chief BD Officer, Flagship Pioneering

Debra Peattie, Managing Partner, SV Investment

Stu Mackey, Global Head, BD, Daiichi Sankyo

Moderator: Bob Silverman, CBO, Turbine Simulated Cell Technologies

​​

4:40 pm

INVESTOR PERSPECTIVES IN ELECTION SEASON

Dean Dimizas, Managing Director, Cambridge Associates

Ansbert Gadicke, Managing Partner, MPM BioImpact

Yigal Nochomovitz, Director, SMid Cap Biotech Analyst, Citi Research

Claudine Prowse, Venture Partner, JP Morgan Asset Management 

Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund​

​

5:10 pm 

COCKTAIL RECEPTION